Yahoo Finance Phibro Animal Health Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Phibro Animal Health (NASDAQ:PAHC) Full Year 2024 Results
Key Financial Results
Revenue: US$1.02b (up 4.1% from FY 2023).
Net income: US$2.42m (down 93% from FY 2023).
Profit margin: 0.2% (down from 3.3% in FY 2023).
EPS: US$0.06 (down from US$0.81 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Phibro Animal Health Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates by 82%.
The primary driver behind last 12 months revenue was the Animal Health segment contributing a total revenue of US$706.5m (69% of total revenue). Notably, cost of sales worth US$704.1m amounted to 69% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to US$217.9m (70% of total expenses). Explore how PAHC's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US.
Performance of the American Pharmaceuticals industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
You still need to take note of risks, for example - Phibro Animal Health has 4 warning signs (and 1 which can't be ignored) we think you should know about.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
